Factory 99% Pioglitazone HCl Powder CAS 112529-15-4 Chemical Intermediate Pioglitazone HCl

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A704
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Pioglitazone HCl
• CAS: 112529-15-4
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Pioglitazone HCl
Appearance	White Powder
CAS NO.	112529-15-4
MF	C19H21ClN2O3S
Storage	Keep in a cool, dry, dark location

 

Pioglitazone HCl is an oral antidiabetic agent used primarily in the management of type 2 diabetes mellitus. It functions by increasing sensitivity and reducing resistance, thereby lowering blood glucose levels. Its use should be tailored to individual patient needs, considering both its benefits and potential risks.

 

1. Type 2 Diabetes Mellitus: Pioglitazone HCl is prescribed for the treatment of type 2 diabetes, particularly in patients who are not adequately controlled with diet and exercise alone or who are already on other oral antidiabetic medications.
2. Combination Therapy: It can be used in combination with other oral antidiabetic agents, such as sulfonylureas or metformin, to further enhance glycemic control.
3. Resistance: Pioglitazone HCl is also indicated for the improvement of sensitivity in patients with resistance, which may help in reducing the risk of cardiovascular complications associated with diabetes.

1. Sensitization: The primary function of Pioglitazone HCl is to increase sensitivity in target tissues, such as muscle, fat, and liver. This allows for better utilization of glucose by these tissues, thereby lowering blood glucose levels.
2. Reduction of Resistance: By activating peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipocytes, Pioglitazone HCl promotes adipocyte differentiation and reduces adipogenesis, which helps in alleviating resistance.
3. Cardiovascular Benefits: In addition to its glycemic effects, Pioglitazone HCl has been shown to have beneficial effects on the cardiovascular system, including improvements in endothelial function and reductions in inflammatory markers. However, its cardiovascular benefits should be weighed against potential risks, such as weight gain and fluid retention.